Skip to main content
Retour
RMD logo

ResMed Inc.

Qualité des données : 100%
RMD
NYSE Healthcare Medical - Instruments & Supplies
228,19 €
▲ 0,22 € (0,10%)
Cap. Boursière : 33,31B
Fourchette du Jour
224,92 € 231,45 €
Fourchette 52 Semaines
199,92 € 293,81 €
Volume
1 000 692
Moyenne 50J / 200J
252,88 € / 260,16 €
Clôture Précédente
227,97 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 23,8 0,3
P/B 5,6 2,9
ROE % 25,9 3,7
Net Margin % 27,2 3,8
Rev Growth 5Y % 12,6 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
295,88 € +29.7%
Low: 265,00 € High: 345,00 €
P/E Prévisionnel
20,6
BPA Prévisionnel
11,05 €
Croissance BPA (est.)
+0,0%
CA Est.
5,6 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 16,20 €
15,91 € – 16,44 €
7,8 B 4
FY2029 14,38 €
14,13 € – 14,59 €
7 B 3
FY2028 13,43 €
12,12 € – 14,29 €
6,5 B 9

Points Clés

Revenue grew 12,64% annually over 5 years — strong growth
Earnings grew 37,20% over the past year
ROE of 25,86% indicates high profitability
Net margin of 27,22% shows strong profitability
Debt/Equity of 0,14 — conservative balance sheet
Generating 1,66B in free cash flow

Croissance

Revenue Growth (5Y)
12,64%
Revenue (1Y)9,84%
Earnings (1Y)37,20%
FCF Growth (3Y)72,37%

Qualité

Return on Equity
25,86%
ROIC18,53%
Net Margin27,22%
Op. Margin32,75%

Sécurité

Debt / Equity
0,14
Current Ratio3,44
Interest Coverage133,66

Valorisation

P/E Ratio
23,78
P/B Ratio5,58
EV/EBITDA19,55
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9,84% Revenue Growth (3Y) 10,39%
Earnings Growth (1Y) 37,20% Earnings Growth (3Y) 24,92%
Revenue Growth (5Y) 12,64% Earnings Growth (5Y) 31,08%
Profitability
Revenue (TTM) 5,15B Net Income (TTM) 1,40B
ROE 25,86% ROA 17,14%
Gross Margin 59,36% Operating Margin 32,75%
Net Margin 27,22% Free Cash Flow (TTM) 1,66B
ROIC 18,53% FCF Growth (3Y) 72,37%
Safety
Debt / Equity 0,14 Current Ratio 3,44
Interest Coverage 133,66 Dividend Yield 0,01%
Valuation
P/E Ratio 23,78 P/B Ratio 5,58
P/S Ratio 6,47 PEG Ratio 0,72
EV/EBITDA 19,55 Dividend Yield 0,01%
Market Cap 33,31B Enterprise Value 32,95B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5,15B 4,69B 4,22B 3,58B 3,20B
Net Income 1,40B 1,02B 897,56M 779,44M 474,51M
EPS (Diluted) 9,51 6,92 6,09 5,30 3,24
Gross Profit 3,05B 2,66B 2,36B 2,02B 1,84B
Operating Income 1,69B 1,32B 1,13B 1,00B 903,68M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,17B 6,87B 6,75B 5,10B 4,73B
Total Liabilities 2,21B 2,01B 2,62B 1,74B 1,84B
Shareholders' Equity 5,97B 4,86B 4,13B 3,36B 2,89B
Total Debt 851,81M 873,94M 1,58B 917,55M 793,72M
Cash & Equivalents 1,21B 238,36M 227,89M 273,71M 295,28M
Current Assets 3,51B 2,36B 2,37B 1,93B 1,57B
Current Liabilities 1,02B 910,66M 758,53M 689,30M 911,77M

Scores de Stratégies

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
#932 of 1052
24
#187 of 218
25
#203 of 332
46
Custom Balanced Risk
#94 of 151
43
Custom Lower Risk
#120 of 140
34

Activité Récente

Entré Cash Flow Compounder
Mar 25, 2026
Entré Capital Light Compounder
Mar 25, 2026
Entré Balanced Risk
Mar 25, 2026
Entré Lower Risk
Mar 25, 2026
Entré Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026